CardioFocus completed the acquisition of the electrophysiology technology division from Galvanize Therapeutics.

CardioFocus, a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, completed the acquisition of the electrophysiology technology division from Galvanize Therapeutics, an energy-based medical device technology. Financial terms were not disclosed. "We look forward to welcoming Centauri users in the EU and recognize the important contribution these clinicians have made to our understanding of focal pulse field ablation. Through this acquisition we will expand our presence in Europe and the UK while supporting and growing our global HeartLight X3 and Centauri customer bases. We are dedicated to improving patient outcomes and optimizing clinical workflow. This acquisition strengthens our leadership position as we innovate the next generation of pulsed field technologies for both focal and true single shot ablation," Steve Ogilvie, CardioFocus CEO.